Ponatinib/Blinatumomab Displays Efficacy as a Chemo-Free, HSCT-Sparing Option in Ph+ ALL
September 28th 2022In an interview before the conference, Fadi G. Haddad, MD, discussed the updated results from the combination of blinatumomab and ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Read More
Debating the Significance of MRD in Blood Cancers vs Initial Patient Characteristics
September 28th 2022In the myeloma space, minimal residual disease negativity is prognostic of progression-free survival in relapsed or refractory patients. In leukemia, the biomarker combined with other prognostication techniques provides complex information that is clinically relevant.
Read More
Lenvatinib/Pembrolizumab Appears Safe in Metastasized Anaplastic Thyroid Carcinoma
September 13th 2022Data presented during the 2022 ESMO Congress showed lenvatinib plus pembrolizumab to elicit an objective response rate of 34.3% after 3 months in evaluable patients, meeting the primary end point of the phase 2 ATLEP trial.
Read More
Belzutifan/Cabozantinib Combo is Well Tolerated in Treatment-Naïve Advanced Clear Cell RCC
September 12th 2022The combination of belzutifan and cabozantinib was well tolerated in patients with treatment-naïve advanced clear cell renal cell carcinoma, according to findings presented at the 2022 ESMO Congress.
Read More
KEYNOTE-522 Trial of Pembrolizumab Does Not Negatively Affect HRQOL Outcomes in TNBC
September 12th 2022Pembrolizumab in the neoadjuvant and adjuvant settings demonstrated similar health-related quality-of-life scores in patients with triple-negative breast cancer when compared with placebo.
Read More
Pembrolizumab and Olaparib Combo Did Not Significantly Improve PFS and OS in mCRPC
September 12th 2022No statistically significant improvement in radiographic progression-free survival and overall survival was seen with pembrolizumab plus olaparib in metastatic castration-resistant prostate cancer.
Read More
2-Year ADT Plus Radiotherapy Following Surgery Improves MFS in Prostate Cancer
September 12th 2022The addition of 2 years of androgen-deprivation therapy to radiotherapy after radical prostatectomy improved metastasis-free survival and time to salvage therapy in patients with prostate cancer.
Read More
Primary End Point of Improved DFS Not Met With Adjuvant Canakinumab in NSCLC
September 12th 2022Adjuvant treatment with canakinumab did not meet the disease-free survival primary end point in patients with completely resected non–small cell lung cancer versus placebo, nor did subgroup analyses show statistically significant differences in DFS, according to results from the phase 3 CANOPY-A trial presented at ESMO Congress 2022.
Read More
RLY-4008 Shows DCR of 100% in FGFR+ Cholangiocarcinoma
September 11th 2022A novel FGFR inhibitor, RLY-4008, induced high response rates and encouraging durability in patients with FGFR inhibitor–naïve cholangiocarcinoma harboring an FGFR2 fusion or rearrangement, according to data from the phase 1/2 ReFocus trial presented at the 2022 ESMO Congress.
Read More
Neoadjuvant Nivolumab/Ipilimumab Shows Unprecedented Pathologic Responses in dMMR Colon Cancer
September 11th 2022At the 2022 ESMO Congress, results from the NICHE-2 trial showed neoadjuvant immunotherapy in patients with mismatch repair deficient colon cancer had notable responses to the therapy well above neoadjuvant chemotherapy.
Read More